A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2026-05-01

Summary

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after failure of at least one prior line of chemotherapy.

• Phase: PHASE3

Details

• Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
• Collaborator: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
• Treatments: Capecitabine; eribulin; Gemcitabine; Vinorelbine